In addition, dasatinib has been reported to inhibit migration of melanoma [53] and sarcoma [54] cell lines, and treatment of A549 cells with dasatinib resulted in inhibition of TGFβ-1-induced migration. This evidence concerns the gene TGFB1 and sarcoma.